28
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Significance

          COVID-19 is a global pandemic currently lacking an effective cure. We used a cell-based infection assay to screen more than 3,000 agents used in humans and animals and identified 15 with antiinfective activity, ranging from 0.1 nM to 50 μM. We then used in vitro enzymatic assays combined with computer modeling to confirm the activity of those against the viral protease and RNA polymerase. In addition, several herbal medicines were found active in the cell-based infection assay. To further evaluate the efficacy of these promising compounds in animal models, we developed a challenge assay with hamsters and found that mefloquine, nelfinavir, and extracts of Ganoderma lucidum (RF3), Perilla frutescens, and Mentha haplocalyx were effective against SARS-CoV-2 infection.

          Abstract

          The outbreak of COVID-19 caused by SARS-CoV-2 has resulted in more than 50 million confirmed cases and over 1 million deaths worldwide as of November 2020. Currently, there are no effective antivirals approved by the Food and Drug Administration to contain this pandemic except the antiviral agent remdesivir. In addition, the trimeric spike protein on the viral surface is highly glycosylated and almost 200,000 variants with mutations at more than 1,000 positions in its 1,273 amino acid sequence were reported, posing a major challenge in the development of antibodies and vaccines. It is therefore urgently needed to have alternative and timely treatments for the disease. In this study, we used a cell-based infection assay to screen more than 3,000 agents used in humans and animals, including 2,855 small molecules and 190 traditional herbal medicines, and identified 15 active small molecules in concentrations ranging from 0.1 nM to 50 μM. Two enzymatic assays, along with molecular modeling, were then developed to confirm those targeting the virus 3CL protease and the RNA-dependent RNA polymerase. Several water extracts of herbal medicines were active in the cell-based assay and could be further developed as plant-derived anti–SARS-CoV-2 agents. Some of the active compounds identified in the screen were further tested in vivo, and it was found that mefloquine, nelfinavir, and extracts of Ganoderma lucidum (RF3), Perilla frutescens, and Mentha haplocalyx were effective in a challenge study using hamsters as disease model.

          Related collections

          Most cited references59

          • Record: found
          • Abstract: found
          • Article: not found

          SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

          Summary The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

            Summary The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000 deaths. Coronavirus spike (S) glycoproteins promote entry into cells and are the main target of antibodies. We show that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, correlating with the efficient spread of SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S1/S2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and SARS-related CoVs. We determined cryo-EM structures of the SARS-CoV-2 S ectodomain trimer, providing a blueprint for the design of vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S murine polyclonal antibodies potently inhibited SARS-CoV-2 S mediated entry into cells, indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Proteomics. Tissue-based map of the human proteome.

              Resolving the molecular details of proteome variation in the different tissues and organs of the human body will greatly increase our knowledge of human biology and disease. Here, we present a map of the human tissue proteome based on an integrated omics approach that involves quantitative transcriptomics at the tissue and organ level, combined with tissue microarray-based immunohistochemistry, to achieve spatial localization of proteins down to the single-cell level. Our tissue-based analysis detected more than 90% of the putative protein-coding genes. We used this approach to explore the human secretome, the membrane proteome, the druggable proteome, the cancer proteome, and the metabolic functions in 32 different tissues and organs. All the data are integrated in an interactive Web-based database that allows exploration of individual proteins, as well as navigation of global expression patterns, in all major tissues and organs in the human body. Copyright © 2015, American Association for the Advancement of Science.
                Bookmark

                Author and article information

                Journal
                Proc Natl Acad Sci U S A
                Proc Natl Acad Sci U S A
                pnas
                pnas
                PNAS
                Proceedings of the National Academy of Sciences of the United States of America
                National Academy of Sciences
                0027-8424
                1091-6490
                02 February 2021
                15 January 2021
                15 January 2021
                : 118
                : 5
                : e2021579118
                Affiliations
                [1] aGenomics Research Center, Academia Sinica , Taipei 115, Taiwan;
                [2] bSchool of Pharmacy, National Taiwan University , Taipei 110, Taiwan;
                [3] cInstitute of Chemistry, Academia Sinica , Taipei 128, Taiwan;
                [4] dDepartment of Chemistry, The Scripps Research Institute , La Jolla, CA 92037
                Author notes

                Contributed by Chi-Huey Wong, December 11, 2020 (sent for review October 16, 2020; reviewed by Michael D. Burkart, Kuo-Hsiung Lee, and Yasuhiro Kajihara)

                Author contributions: C.M., S.-C.H., and C.-H.W. designed research; J.-T.J., T.-J.R.C., H.-H.M., Y.-T.W., C.M., and S.-C.H. performed research; T.-J.R.C., W.-B.Y., T.-H.C., J.-J.S., W.-C.C., R.-J.C., and S.-S.M. contributed new reagents/analytic tools; J.-T.J. and T.-J.R.C. performed assays; Y.-T.W. did the modeling; C.M. analyzed protein data; J.-T.J., T.-J.R.C., Y.-P.J., Y.-T.W., C.-W.C., X.C., P.-H.L., C.M., S.-C.H., and C.-H.W. analyzed data; and Y.-P.J., P.-H.L., S.-C.H., and C.-H.W. wrote the paper.

                Reviewers: M.D.B., University of California, San Diego; K.-H.L., University of North Carolina at Chapel Hill; and Y.K., Osaka University.

                Author information
                https://orcid.org/0000-0003-4297-018X
                https://orcid.org/0000-0002-9680-4307
                https://orcid.org/0000-0003-0156-963X
                https://orcid.org/0000-0003-3491-8920
                https://orcid.org/0000-0002-4492-0883
                https://orcid.org/0000-0003-4336-6304
                https://orcid.org/0000-0003-0856-214X
                https://orcid.org/0000-0002-0119-8288
                https://orcid.org/0000-0001-6668-4642
                https://orcid.org/0000-0002-4741-2307
                https://orcid.org/0000-0002-8797-729X
                Article
                202021579
                10.1073/pnas.2021579118
                7865145
                33452205
                ef8872df-890d-4208-af84-c603b965facb
                Copyright © 2021 the Author(s). Published by PNAS.

                This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).

                History
                Page count
                Pages: 8
                Funding
                Funded by: Ministry of Science and Technology, Taiwan (MOST) 501100004663
                Award ID: MOST 108-3114-Y-001-002
                Award ID: MOST 109-0210-01-18-02
                Award Recipient : Jia-Tsrong Jan Award Recipient : Ting-Jen Rachel Cheng Award Recipient : Yu-Pu Juang Award Recipient : Hsiu-Hua Ma Award Recipient : Ying-Ta Wu Award Recipient : Wen-Bin Yang Award Recipient : Cheng-Wei Cheng Award Recipient : Xiaorui Chen Award Recipient : Ting-Hung Chou Award Recipient : Jiun-Jie Shie Award Recipient : Wei-Chieh Cheng Award Recipient : Rong-Jie Chein Award Recipient : Shi-Shan Mao Award Recipient : Pi-Hui Liang Award Recipient : Che Ma Award Recipient : Shang-Cheng Hung Award Recipient : Chi-Huey Wong
                Funded by: Academia Sinica 501100001869
                Award ID: AS-SUMMIT-109
                Award ID: AS-KPQ-109-BioMed
                Award Recipient : Jia-Tsrong Jan Award Recipient : Ting-Jen Rachel Cheng Award Recipient : Yu-Pu Juang Award Recipient : Hsiu-Hua Ma Award Recipient : Ying-Ta Wu Award Recipient : Wen-Bin Yang Award Recipient : Cheng-Wei Cheng Award Recipient : Xiaorui Chen Award Recipient : Ting-Hung Chou Award Recipient : Jiun-Jie Shie Award Recipient : Wei-Chieh Cheng Award Recipient : Rong-Jie Chein Award Recipient : Shi-Shan Mao Award Recipient : Pi-Hui Liang Award Recipient : Che Ma Award Recipient : Shang-Cheng Hung Award Recipient : Chi-Huey Wong
                Categories
                422
                530
                Biological Sciences
                Medical Sciences
                Custom metadata
                free

                sars-cov-2,drug repurposing,antiviral,cell-based and animal studies

                Comments

                Comment on this article